60% i MabThera gruppen i hele behandlingsperioden på 2 år, hvorimod den faldt i observationsgruppen (36% efter 2 år).
The proportion of patients with IgG levels below the LLN was about 60% in the MabThera group throughout the 2 year treatment period, while it decreased in the observation group (36% after 2 years).